Home Cart Sign in  
Chemical Structure| 2704617-96-7 Chemical Structure| 2704617-96-7

Structure of CFT8634
CAS No.: 2704617-96-7

Chemical Structure| 2704617-96-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CFT8634 is an orally active BRD9-targeted degrader used in research on synovial sarcoma and SMARCB1-deficient solid tumors.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CFT8634

CAS No. :2704617-96-7
Formula : C37H45F3N6O5
M.W : 710.79
SMILES Code : CC=1C(C2=CC(OC)=C(CN3CC(F)(F)[C@H](CC3)N4CCN(CC4)C5=C(F)C=C(N[C@@H]6C(=O)NC(=O)CC6)C=C5)C(OC)=C2)=CN(C)C(=O)C1C
MDL No. :MFCD34662946

Safety of CFT8634

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of CFT8634

epigenetics

Isoform Comparison

Biological Activity

Description
CFT8634 is an orally active degrader targeting BRD9, derived from patent WO2021178920A1 compound 174, and is researched for synovial sarcoma and SMARCB1-deleted solid tumors[1][2].
Target
  • BET

    BRD9, DC50:3 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05355753 Synovial Sarcoma|Soft Tissue S... More >>arcoma Less << PHASE1 TERMINATED 2023-12-19 City of Hope, Duarte, Californ... More >>ia, 91010, United States|Sarcoma Oncology Research Center, Santa Monica, California, 90403, United States|University of Colorado - Aurora Cancer Center, Aurora, Colorado, 80045, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, 32224, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, 52242, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|Mayo Clinic - Rochester, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, 10021, United States|Columbia University, New York, New York, 10027, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.41mL

0.28mL

0.14mL

7.03mL

1.41mL

0.70mL

14.07mL

2.81mL

1.41mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories